Moderna, Inc. (MRNA) announced late Thursday that the U.S. Food and Drug Administration (FDA) has approved its respiratory syncytial virus (RSV) vaccine for adults aged 18-59 with underlying ...

Despite questions coming from federal changes, Colorado’s chief medical officer says he thinks “there will be enough vaccines ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also get it. RSV usually causes mild, cold-like symptoms such as cough, ...

While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable. 1 Over one-third of adults aged 18-59 years ...

But its financial fortunes have reversed since then due to declining demand for COVID-19 shots and slow uptake for an RSV vaccine it’s also brought to market. Moderna has revised its revenue guidance ...

To date, Moderna has received marketing authorizations for its RSV vaccine in the United States, the European Union, Canada, Qatar, the United Arab Emirates, Taiwan, and the United Kingdom and has ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over upcoming COVID and RSV sales.

This approval was supported by results from Moderna's Phase 3 study (NCT06067230), which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions ...